NCT03147378 is a Phase 1 clinical trial of ModraDoc006/r in Solid Tumor, Adult, sponsored by Modra Pharmaceuticals.

Who is sponsoring NCT03147378?

NCT03147378 is sponsored by Modra Pharmaceuticals.

What drugs are being tested in NCT03147378?

Interventions in NCT03147378: ModraDoc006/r.

What condition does NCT03147378 study?

NCT03147378 studies Solid Tumor, Adult.

Is NCT03147378 still recruiting?

NCT03147378 is currently completed. Last updated 19 October 2021.

Last reviewed 2021-10-19 · How we verify

NCT03147378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Food Effect Study of ModraDoc006 in Combination With Ritonavir

Completed Phase 1 Last updated 19 October 2021

What this trial tests

Phase 1 trial testing ModraDoc006/r in Solid Tumor, Adult in 18 participants. Completed in 4 April 2018.

Timeline

10 May 2017

Primary endpoint
4 April 2018

4 April 2018

Quick facts

Lead sponsor	Modra Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	10 May 2017
Primary completion	4 April 2018
Estimated completion	4 April 2018
Sites	1 location across Netherlands

Drugs / interventions tested

ModraDoc006/r — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

Modra Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effect of food on the pharmacokinetics of ModraDoc006 in combination with ritonavir, in an open-label, cross-over design. Patients will be randomized into two treatment groups receiving ModraDoc006/r week 1 under fasting and week 2 under fed condition, or vice versa.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
Energy metabolism in health and diseases.
Liu H, Wang S, Wang J, Guo X, et al · · 2025 · cited 178× · PMID 39966374 · DOI 10.1038/s41392-025-02141-x
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
Vermunt MAC, de Weger VA, Janssen JM, Lopez-Yurda MI, et al · · 2021 · cited 2× · PMID 33464545 · DOI 10.1007/s40268-020-00336-x

Verify or expand the search:

Other trials of ModraDoc006/r

Trials testing the same drug.

NCT04028388 — ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer · Phase 2 · completed
NCT03890744 — ModraDoc006/r in Patients With Breast Cancer · Phase 2 · completed
NCT03150368 — Extended Use of ModraDoc006/r · Phase 1 · completed
NCT03136640 — ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer · Phase 1 · completed

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other Modra Pharmaceuticals trials

Trials by the same sponsor.

NCT04028388 — ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer · Phase 2 · completed
NCT03890744 — ModraDoc006/r in Patients With Breast Cancer · Phase 2 · completed
NCT03150368 — Extended Use of ModraDoc006/r · Phase 1 · completed
NCT03136640 — ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03147378 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Modra Pharmaceuticals
Last refreshed: 19 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03147378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing